Frau PD. Sabine Fischer, MD

Previous and current research


  • epidemiology and pathophysiology of hyperlipoproteinemia
  • therapy of different types of hyperlipoproteinemia
  • diagnostic approach to and therapy of obesity
  • therapy of type 2 diabetes
  • Molecular mechanisms of type 2 diabetes

Publications


  1. Hanefeld M, Haffner SM, Menschikowski M, Köhler C, Temelkova-Kurktschiev T, Wildbrett J, Fischer S. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Research and Clinical Practice (2002) 55:221-227
  2. Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Köhler C, Wildbrett J, Fücker K, Temelkova-Kurktschiev T, Hanefeld M. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes, Obesity and Metabolism (2003) 5: 38-44
  3. Fischer S, Julius U, Hanefeld M, Fücker K, Gräßler J, Towers W, Schwanebeck U, Schulze J, Schwarz P. Das Vorkommen vom Genotyp 1.1 im SNP-44 des CAPN10-Gens ist im Stadium des Typ-2-diabetes mit erhöhten Insulin- und C-Peptid-Werten assoziiert. Diabetes und Stoffwechsel (2004) 13:3-9
  4. Pistrosch F, Passauer J, Fischer S, Fücker K, Hanefeld M, Gross P. In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose Control. Diabetes Care (2004) 27/2:484490
  5. Fischer S, Hanefeld M, Müller-Wieland D, Windler E, Rothe U. Praxisleitlinie zur Diagnostik und Therapie von Fettstoffwechselstörungen. Institut für Medizinische Informatik und Biometrie der TU Dresden. Thieme, Meißen (2005)
  6. Fischer S. Risk adapted therapy of vascular diseases-basic therapy of dys- and hyperlipoproteinemia. Z Kardiol (2005) Suppl 4: iv24-iv27
  7. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone Improves Glomerular Hyperfiltration, Renal Endothelial Dysfunction, and Microalbuminuria of Incipient Diabetic Nephropathy in Patients. Diabetes (2005) 54:2206-2211
  8. Pistrosch F, Herbrig K, Oelschlägel U, Richter S, Passauer J, Fischer S, Gross P. PPAR¡-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis (2005) 183:163-167

Curriculum vitae

1976: MD at the University of Technology Dresden

1979: specialist in internal medicine

1990: lecturing qualification (Habilitation) "Some aspects of the pathogenesis of
obesity – the metabolic basis of altered energy utilisation"


1991: higher lecturing qualification (Venia legendi) in internal medicine

1991: qualified in diabetic medicine

1992: senior physician at the 3rd Medical Clinic of the University Hospital Dresden

1995: non-staff lecturer

nach oben